Navigation Links
Orqis(R) Medical's Cancion(R) System Significantly Increases Cardiac Performance
Date:4/1/2008

MOMENTUM Trial Results Presented at the American College of Cardiology

Annual Meeting

CHICAGO, April 1, 2008 /PRNewswire/ -- Orqis(R) Medical Corporation, a medical products company developing and marketing devices to treat heart failure, announced today that the company's MOMENTUM Trial results were presented during the Late Breaking Clinical Trials session at the annual American College of Cardiology (ACC) meeting in Chicago. The MOMENTUM Trial evaluated the percutaneous Cancion System in patients hospitalized with heart failure.

Barry Greenberg, M.D., Director, Advanced Heart Failure Treatment Program, University of California San Diego Medical Center, and National Principal Investigator for the MOMENTUM Trial, presented, "Efficacy and Safety of Continuous Aortic Flow Augmentation in Patients Hospitalized with Acute Decompensated Heart Failure: Results of the MOMENTUM Trial."

"While the MOMENTUM Trial did not meet its primary composite efficacy endpoint, MOMENTUM is a landmark study demonstrating that the Cancion System, in combination with conventional medical (drug) treatment, statistically significantly improved cardiac performance compared with drug treatment alone," stated Dr. Greenberg. He continued, "There has been very little progress in identifying effective new approaches for treating patients with decompensated heart failure and the Cancion System provides physicians with a needed new treatment option."

Mr. Ken Charhut, President and CEO, Orqis Medical, stated, "MOMENTUM proved that the Cancion System significantly improves cardiac performance." He continued, "Orqis' unique aortic flow therapy bridges the gap between medical management and more invasive procedures without ever touching the heart." The Cancion System is currently available in markets outside the U.S.

About Heart Failure

Over 5 million Americans suffer from heart failure, a condition in which the heart becomes weakened and cannot pump blood efficiently. Heart failure is caused by coronary artery disease, past myocardial infarctions, cardiomyopathy and other underlying cardiovascular disorders, and it is characterized by shortness of breath, functional impairment, and edema. In the U.S., heart failure results in over 1 million hospitalizations annually and is responsible for over $33 billion in direct and indirect costs to the U.S. healthcare system each year.

About Orqis Medical Corporation

Orqis Medical Corporation is a privately held medical device company that develops and sells minimally invasive devices that improve cardiac performance through aortic flow therapy. Orqis devices uniquely bridge the treatment gap between medical management and more invasive procedures without ever touching the heart. The percutaneous Cancion System has secured the CE mark. The implantable Exeleras(R) System is in development.

For more information on Orqis Medical, please visit http://www.orqis.com

Note: Orqis(R), Cancion(R), and Exeleras(R) are registered trademarks of Orqis Medical Corporation.


'/>"/>
SOURCE Orqis Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Velos to Develop Key System Interface for Clinical Research
2. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
3. St. Jude Finds Signaling System That Halts the Growth of a Childhood Brain Cancer
4. Inclinix Announces New Patent for Expert System Platform
5. PLC Systems Reports Fourth Quarter 2007 Results
6. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
7. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
8. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds
9. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
10. Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System
11. Data Demonstrate that Obagi Medical Products Condition & Enhance Skin Care System is an Effective Complement to Facial Rejuvenation Procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... SAN DIEGO , Oct. 12, 2017 ... has recognized the company with their  2017 New Product Innovation ... is based on extensive primary and secondary medical device market ... AVACEN Medical, through its first-to-market OTC, drug-free pain relief product, ... a unique approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers ... an innovative way to use nonlinear optical imaging to ... new drugs. ... will show how researchers from BioPharmX and the Wellman ... used a suite of imaging techniques in what is ...
(Date:10/11/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an update ... Puerto Rico , where the company manufactures ... Following a comprehensive onsite assessment, the ... temporary loss of power and minimal water damage due ... have resumed, and the company expects to return to ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
Breaking Medicine News(10 mins):